For patients with allogeneic transplants, intratumoral anti-PD-1 treatment combined with TLR9 agonist can ensure a strong anti-tumor immune response while avoiding severe transplant rejection caused by systemic immunotherapy, reflecting the unique effectiveness and safety of intratumoral injection (57). This evidence concerns the gene PDCD1 and neoplasm.